David Tsao Sells 20,000 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 20,000 shares of the stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $98.77, for a total transaction of $1,975,400.00. Following the completion of the sale, the chief technology officer owned 1,000 shares of the company’s stock, valued at $98,770. This trade represents a 95.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Tuesday, August 25th, David Tsao sold 10,000 shares of Billiontoone stock. The stock was sold at an average price of $100.00, for a total transaction of $1,000,000.00.
• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The shares were sold at an average price of $92.86, for a total transaction of $928,600.00.
• On Monday, June 15th, David Tsao sold 20,000 shares of Billiontoone stock. The shares were sold at an average price of $102.27, for a total transaction of $2,045,400.00.

Billiontoone Trading Up 0.3%

BLLN opened at $98.77 on Friday. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. The company’s 50 day simple moving average is $111.64 and its two-hundred day simple moving average is $95.81. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $150.44. The firm has a market capitalization of $4.66 billion and a price-to-earnings ratio of 141.10.

Billiontoone (NASDAQ:BLLN) last issued its earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, hitting the consensus estimate of $0.15. The business had revenue of $109.45 million for the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. Analysts expect that Billiontoone, Inc. will post 0.83 EPS for the current fiscal year.

Institutional Investors Weigh In On Billiontoone

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BLLN. Adams Street Partners LLC purchased a new stake in Billiontoone in the fourth quarter valued at $140,063,000. Wasatch Advisors LP grew its holdings in shares of Billiontoone by 40.2% during the 2nd quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock worth $62,160,000 after purchasing an additional 148,446 shares during the period. Price T Rowe Associates Inc. MD acquired a new stake in shares of Billiontoone during the 4th quarter worth about $39,717,000. JPMorgan Chase & Co. purchased a new stake in Billiontoone in the 4th quarter valued at about $32,078,000. Finally, Emerald Advisers LLC raised its holdings in Billiontoone by 26.8% in the 1st quarter. Emerald Advisers LLC now owns 239,562 shares of the company’s stock valued at $18,911,000 after buying an additional 50,613 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on BLLN. BTIG Research dropped their target price on Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Canaccord Genuity Group began coverage on Billiontoone in a report on Wednesday, September 2nd. They set a “buy” rating and a $120.00 price target on the stock. Zacks Research cut shares of Billiontoone from a “hold” rating to a “strong sell” rating in a research report on Monday, August 31st. Wall Street Zen lowered shares of Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating for the company in a research report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $125.88.

Billiontoone Company Profile

BillionToOne, Inc is a molecular diagnostics company that develops blood-based tests designed to provide genetic and health information from small amounts of biological material. The company’s technology uses its proprietary quantitative counting template approach to improve the accuracy and sensitivity of molecular testing.

The company’s primary offerings include UNITY, a portfolio of prenatal genetic tests. These services support screening for chromosomal conditions, single-gene disorders and carrier status, and are designed to help healthcare providers assess fetal and maternal genetic risks using a maternal blood sample.